IRX's Principal Activity is the developing and commercializing medical diagnostic and monitoring technology and digitally enabled drug delivery systems.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||+46.65%|
|ASX Rank||1,817 of 2,316|
|Sector Rank||170 of 198|
InhaleRx Limited (IRX, formerly Lifespot Health Ltd ) focus on medical inhalation devices for the delivery of prescribed medicines.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Mr Sean Williams||Non-Executive Chairman,Non-Executive Director||Jul 2021||
Mr Sean Williams
Non-Executive Chairman,Non-Executive Director
Mr Williams is an experienced senior executive who has had a career across the supply chain, health, pharmaceutical and investment management sectors. Most recently Sean was CEO of an agricultural investment company. The earlier parts of Sean's career were spent in senior operational and finance roles with multi-national and listed local companies, having initially commenced his career with KPMG. He spent a number of years as General Manager Finance and General Manager - Hospital Pharmacy & Dental Distribution Services for Symbion Pharmacy Services. He has also worked in private equity and with private equity investments, including 5 years as CFO of Silk Logistics Group, and has focused on entrepreneurial ventures, including as a business owner, founder and CEO of businesses featuring management buy-outs, business mergers and start-ups.
|Dr Andrew Saich||Non-Executive Director||Jul 2021||
Dr Andrew Saich
Dr Saich has worked in both large and small pharmaceutical companies. He has been involved in pharmaceutical Industry for over 20 years and has gained experience of international management, medicines commercialization and pharmaceutical R&D. Andrew is currently Chief Medical Officer of Return Health, a US based biotech company developing novel psychedelic treatments for patients with dementia and a co-founder of Diligenc. Capital, a cannabinoid prescription medicines investment group and Diligenc. Pathways, a consultancy comprising senior cannabinoid specialists from the ex-GW Pharmaceuticals team. In previous roles, Andrew was the European Medical Director responsible for establishing the Intercept Pharmaceuticals international medical and commercial organization as the company expanded from its New York corporate headquarters into thirteen countries across Europe. In 2016 Andrew created and led the GW Pharmaceuticals International Medical organization in preparation for the launch of Epidyolex (cannabidiol) for the treatment of rare and debilitating drug-resistant epilepsies. GW Pharmaceuticals (recently acquired by Jazz Pharmaceuticals) was the world leader in the development of cannabinoid medicines and Andrew was a senior member of the international management team, the strategic launch team, the Clinical Development Committee and the Corporate Drug Safety team. Andrew networks with politicians, governmental organizations and pharmaceutical regulators during his time at GW and lead both the global investigator initiated studies program and the global compassionate use program. Post GW Pharmaceuticals Andrew became Chief Medical Officer of Senzer Pharmaceuticals with responsibility for a clinical development program utilizing inhaled cannabinoids.
|Mr Darryl Davies||Non-Executive Director||Jul 2021||
Mr Darryl Davies
Mr Davies has over 15 years' experience in Psychology, Healthcare and Harm Minimisation. He joined Addaction, the substance misuse NGO in the UK that works to transform the lives of people affected by drug and alcohol problems. Darryl developed his experience of harm minimization in Thailand where he worked at several detoxification centers supporting patients from around the world via a combination of Western and Eastern practices. Since migrating to Australia in 2011, Darryl has worked in several for-purpose, NGO roles including Compliance, Business Development, Corporate Relationships, and Educational Social Enterprise. Transitioning into new challenges, Darryl started working with a wellness device start-up in 2016, before becoming something of a medicinal cannabis industry early adopter. Recognizing that changing perceptions was paramount to industry development; Darryl lent on his experience and coordinated a range of targeted cannabis educational events nationally. Darryl has designed and facilitated such events for the State Government and has led doctor education initiatives in regional areas. He is also recognized for his work as a Director with Israeli Company, Cann10 having delivered Australia's first university-based Cannabis Leadership Program. In early 2018, Darryl Co-founded private Medicinal Cannabis Service Provider, Cannvalate Pty Ltd. He has managed the company's award-winning patient access and distribution programs as well as developing the CRO, Medicinal Cannabis Research Collaboration (MCRC). His role of Chief Operating Officer has enabled him to develop a sound understanding of the challenges of scaling effective departments to solve problems in the Australian Medicinal Cannabis landscape. Darryl has global industry connections and is nominated the Australian Director of Canadian manufacturing leader, The Valens Company (VLNCF) whereby he advises on their Australian market entry strategy and he also sits on the Board of Directors for New Zealand cultivation company, Greenfern Industries Limited.
|Ms Elizabeth Spooner||Joint Company Secretary||Jul 2021|
|Ms Nova Taylor||Joint Company Secretary||Jan 2021|
|Mr Matthew Golden||Chief Executive Officer||Oct 2020|
IRX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|11/10/21||Darryl Davies||Buy||+305,248||$0.105||$32,051||On-market trade|
|24/08/21||Darryl Davies||Buy||+1,025,000||$0.097||$99,927||On-market trade|
|05/01/21||Rodney Hannington||Issued||55,000||$0.07||$3,850||Rights issue|
The current holdings of IRX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|M I D Wealth Pty Ltd||03/03/2021||13,100,000||7.78|
|Ela Capital Inc||03/03/2021||14,515,743||8.62|
|Pyxis Holdings Pty Ltd||03/03/2021||8,909,441||5.29|
|Cannvalate Pty Ltd||11/10/2021||33,524,924||19.90|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|11-10-21||Cannvalate Pty Ltd||3,335,302||19.21||19.90|
|19-01-21||Ela Capital Inc||14,515,743||--||8.60|
|05-01-21||Cannvalate Pty Ltd||6,077,525||17.89||19.21|
|13-11-20||M I D Wealth Pty Ltd||13,100,000||--||9.72|
|13-11-20||Pyxis Holdings Pty Ltd||309,426||7.32||6.61|
|06-11-20||Cannvalate Pty Ltd||112,097||19.72||17.89|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.